secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213380
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses
--------------------------------------------------------------------------------

- GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.
- Cash $169.1M at March 31, 2026; expects to fund operations through first half of 2028.
- Phase 1b/2 evorpacept + zanidatamab data: 60% cORR in ccHER2+ patients; all 5 with high CD47 responded (mPFS 22.1 months).
- Phase 2 ASPEN-09-Breast topline data in mid-2027; Phase 1 ALX2004 safety data in 2H 2026.
- Appointed Jeff Knight as Chief Development and Operating Officer in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/0001193125-26-213380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/alxo-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer